Status:
UNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Eligibility:
All Genders
18-90 years
Brief Summary
The studied materials contains surgically specimens of two groups of patiens with non-small cell lung cancer who have received two regimens of induction (neoadjuvant) chemotherapy before tumor resecti...
Detailed Description
Patients with clinical stage IIIA N2 non-small cell lung cancer (NSCLC) have a 5-year survival rate of 10% to 15%, much worse than those of earlier stages of disease. The use of pre-operative (neo-adj...
Eligibility Criteria
Inclusion
- NSCLC patients with stage III in NTUH
- Recieved neoadjuvant chemotherapy and received operation
Exclusion
- Patients who did not received chemotherapy or they did not receive operation.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00797238
Start Date
September 1 2007
End Date
August 1 2010
Last Update
July 15 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 110